When an immune thrombocytopenia (ITP) relapse occurs, it’s always a huge disappointment and reminder that this is an illness that will never go away. Once my platelets become stable, I enter the ...

Patients with PCNSL experience faster cerebral atrophy after consolidation therapy and the rate of atrophy is similar between standard consolidation strategies. Patients with primary central nervous ...

Out of the 38 patients who received rituximab in combination with avatrombopag, 79% responded within 30 days of combination therapy. Real-world data support the potential of avatrombopag for treating ...

The majority of non-responders at Cycle 1 of rozanolixizumab treatment became responders at Cycle 2. Rozanolixizumab significantly improves myasthenia gravis (MG)-specific outcomes compared to placebo ...

The study reported the pooled prevalence estimates for coronary artery disease, congestive heart failure, cerebrovascular diseases, hypertension, and myocardial infarction among patients with MG.

A systematic analysis evaluates the incidence of germline mosaicism in Duchenne muscular dystrophy (DMD), as well as recurrence risks. Evaluation of germline mutations is not the current standard of ...

The patient slowly improved since beginning rituximab and is now able to stand for short periods of time. The second reported case of chronic inflammatory demyelinating polyneuropathy (CIDP) ...

Unlike MS, NMOSD does not respond to immunomodulatory therapy and requires permanent immunosuppression. A review of the current diagnostic and management strategies for neuromyelitis optica spectrum ...